Scimega Research is pleased to announce the launch of its new Reverse Feasibility Resource Center
Scimega Research, (www.scimega.com) the experts in clinical oncology, is pleased to announce the launch of its newReverse Feasibility Resource Centre, a unique initiative that complements its highly successful Reverse Feasibility Program that matches the patient recruitment needs of U.S. oncology sponsors with the scientific interests of Canadian investigators and the treatment needs of their patients.
This microsite will enhance sponsor access to the program by providing regular updates that highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and catchment area size for each of the ten Canadian provinces.
Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. The Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for trials, based on lines of treatment, tumor types and targets.
“The Reverse Feasibility Program was launched in 2009 to attract state-of-the-art clinical research to Canada,” said Denise Deakin, President & co-founder of Scimega Research. “It was founded on the premise that long-standing relationships between Scimega and top performing oncology sites could be leveraged by sponsors to maximize the performance and quality of their trials, while enhancing the overall clinical trial experience for both investigators and patients,” continued Ms. Deakin.
“Using this approach, we’ve seen as much as a 50% reduction is study start-up times, while meeting targeted patient recruitment objectives. It’s really proven to be win-win situation as sponsors are thrilled with the performance metrics, while clinicians and their patients are happy to take participate in well designed, cutting-edge trials. We’re hoping the new Resource Centre will help facilitate many more of these positive experiences.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.